Item 8.01 Other Items.
On September 21, 2021, AbCellera Biologics Inc., (the "Company"), issued a press
release announcing that the European Commission (EC) and Eli Lilly and Company
(Lilly) have entered into a Joint Procurement Agreement to supply up to 220,000
doses of bamlanivimab together with etesivimab to treat confirmed COVID-19 in
patients aged 12 years and older that do not require supplemental oxygen for
COVID-19 and who are at increased risk of progressing to severe COVID-19. A copy
of the press release is attached herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit
No. Description
99.1 Press Release issued by AbCellera Biologics Inc. on September 21, 2021 .
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses